ATE334677T1 - Verwendung des metabolits von valsartan zur hemmung der thrombozytenaggregation - Google Patents
Verwendung des metabolits von valsartan zur hemmung der thrombozytenaggregationInfo
- Publication number
- ATE334677T1 ATE334677T1 AT03749892T AT03749892T ATE334677T1 AT E334677 T1 ATE334677 T1 AT E334677T1 AT 03749892 T AT03749892 T AT 03749892T AT 03749892 T AT03749892 T AT 03749892T AT E334677 T1 ATE334677 T1 AT E334677T1
- Authority
- AT
- Austria
- Prior art keywords
- metabolite
- valsartan
- platelet aggregation
- ischemic
- acute
- Prior art date
Links
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical class C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 2
- 230000002776 aggregation Effects 0.000 title 1
- 238000004220 aggregation Methods 0.000 title 1
- 239000002207 metabolite Substances 0.000 abstract 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- ICSQZMPILLPFKC-XLDIYJRPSA-N 4-Hydroxyvalsartan Chemical compound C1=CC(CN(C(=O)CCC(O)C)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ICSQZMPILLPFKC-XLDIYJRPSA-N 0.000 abstract 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010003178 Arterial thrombosis Diseases 0.000 abstract 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 abstract 1
- 206010008479 Chest Pain Diseases 0.000 abstract 1
- 206010051055 Deep vein thrombosis Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 206010038563 Reocclusion Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 208000032109 Transient ischaemic attack Diseases 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
- 201000010875 transient cerebral ischemia Diseases 0.000 abstract 1
- 229960004699 valsartan Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38037302P | 2002-05-14 | 2002-05-14 | |
| US39501402P | 2002-07-11 | 2002-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE334677T1 true ATE334677T1 (de) | 2006-08-15 |
Family
ID=29423705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03749892T ATE334677T1 (de) | 2002-05-14 | 2003-05-13 | Verwendung des metabolits von valsartan zur hemmung der thrombozytenaggregation |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20050197372A1 (https=) |
| EP (1) | EP1505965B1 (https=) |
| JP (1) | JP4467427B2 (https=) |
| KR (1) | KR101005367B1 (https=) |
| CN (1) | CN100408035C (https=) |
| AT (1) | ATE334677T1 (https=) |
| AU (1) | AU2003267447B8 (https=) |
| BR (1) | BR0310018A (https=) |
| CA (1) | CA2482541A1 (https=) |
| CY (1) | CY1105638T1 (https=) |
| DE (1) | DE60307265T2 (https=) |
| DK (1) | DK1505965T3 (https=) |
| ES (1) | ES2268403T3 (https=) |
| IL (2) | IL164774A0 (https=) |
| MX (1) | MXPA04011282A (https=) |
| NO (1) | NO20045245L (https=) |
| NZ (1) | NZ536295A (https=) |
| PL (1) | PL371728A1 (https=) |
| PT (1) | PT1505965E (https=) |
| RU (1) | RU2334512C2 (https=) |
| TW (1) | TWI299663B (https=) |
| WO (1) | WO2003094915A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| TW200523257A (en) * | 2003-09-26 | 2005-07-16 | Novartis Ag | Use of organic compounds |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| AR068814A1 (es) * | 2007-08-29 | 2009-12-09 | Orion Corp | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso |
| RU2410104C1 (ru) * | 2009-07-10 | 2011-01-27 | Учреждение Российской академии медицинских наук Научный центр неврологии РАМН | СПОСОБ СНИЖЕНИЯ АГРЕГАЦИОННОЙ АКТИВНОСТИ ТРОМБОЦИТОВ in vitro |
| US10478404B2 (en) | 2014-01-24 | 2019-11-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Materials, methods and devices for altering cell reactivity |
| CN110078640B (zh) * | 2019-03-29 | 2022-04-05 | 浙江美诺华药物化学有限公司 | 一种缬沙坦中间体的合成方法 |
| CN111643557B (zh) * | 2020-05-26 | 2022-02-22 | 四川省骨科医院 | 一种防治下肢深静脉血栓后遗症期的药物组合物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE312198T1 (de) * | 1993-04-05 | 2005-12-15 | Univ Utah Res Found | Diagnose und behandlung von supravalvular aortic stenosis |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| CA2379666C (en) * | 1999-07-21 | 2009-10-13 | Takeda Chemical Industries, Ltd. | Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof |
| AU2001267404A1 (en) * | 2000-05-04 | 2001-11-12 | Ipf Pharmaceuticals Gmbh | Novel compounds for the treatment of inflammatory and cardiovascular diseases |
| NZ522953A (en) * | 2000-06-22 | 2005-10-28 | Novartis Ag | Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate |
-
2003
- 2003-05-12 TW TW092112854A patent/TWI299663B/zh not_active IP Right Cessation
- 2003-05-13 IL IL16477403A patent/IL164774A0/xx unknown
- 2003-05-13 AU AU2003267447A patent/AU2003267447B8/en not_active Ceased
- 2003-05-13 MX MXPA04011282A patent/MXPA04011282A/es active IP Right Grant
- 2003-05-13 WO PCT/EP2003/004997 patent/WO2003094915A1/en not_active Ceased
- 2003-05-13 DK DK03749892T patent/DK1505965T3/da active
- 2003-05-13 ES ES03749892T patent/ES2268403T3/es not_active Expired - Lifetime
- 2003-05-13 CA CA002482541A patent/CA2482541A1/en not_active Abandoned
- 2003-05-13 CN CNB03810864XA patent/CN100408035C/zh not_active Expired - Fee Related
- 2003-05-13 EP EP03749892A patent/EP1505965B1/en not_active Expired - Lifetime
- 2003-05-13 RU RU2004136583/15A patent/RU2334512C2/ru not_active IP Right Cessation
- 2003-05-13 BR BR0310018-9A patent/BR0310018A/pt not_active IP Right Cessation
- 2003-05-13 US US10/514,299 patent/US20050197372A1/en not_active Abandoned
- 2003-05-13 KR KR1020047018282A patent/KR101005367B1/ko not_active Expired - Fee Related
- 2003-05-13 AT AT03749892T patent/ATE334677T1/de active
- 2003-05-13 PT PT03749892T patent/PT1505965E/pt unknown
- 2003-05-13 DE DE60307265T patent/DE60307265T2/de not_active Expired - Lifetime
- 2003-05-13 NZ NZ536295A patent/NZ536295A/en not_active IP Right Cessation
- 2003-05-13 PL PL03371728A patent/PL371728A1/xx unknown
- 2003-05-13 JP JP2004503001A patent/JP4467427B2/ja not_active Expired - Lifetime
-
2004
- 2004-10-21 IL IL164774A patent/IL164774A/en not_active IP Right Cessation
- 2004-11-30 NO NO20045245A patent/NO20045245L/no not_active Application Discontinuation
-
2006
- 2006-09-28 CY CY20061101409T patent/CY1105638T1/el unknown
-
2009
- 2009-02-02 US US12/363,926 patent/US20100048654A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003267447A1 (en) | 2003-11-11 |
| KR20050000532A (ko) | 2005-01-05 |
| JP4467427B2 (ja) | 2010-05-26 |
| DE60307265T2 (de) | 2007-07-19 |
| CN1652774A (zh) | 2005-08-10 |
| HK1074395A1 (en) | 2005-11-11 |
| PL371728A1 (en) | 2005-06-27 |
| CY1105638T1 (el) | 2010-12-22 |
| TW200410686A (en) | 2004-07-01 |
| AU2003267447B8 (en) | 2009-08-06 |
| NZ536295A (en) | 2006-12-22 |
| US20100048654A1 (en) | 2010-02-25 |
| JP2005529913A (ja) | 2005-10-06 |
| PT1505965E (pt) | 2006-11-30 |
| MXPA04011282A (es) | 2005-01-25 |
| AU2003267447B2 (en) | 2006-11-02 |
| WO2003094915A1 (en) | 2003-11-20 |
| BR0310018A (pt) | 2005-02-15 |
| CA2482541A1 (en) | 2003-11-20 |
| KR101005367B1 (ko) | 2010-12-30 |
| IL164774A0 (en) | 2005-12-18 |
| DK1505965T3 (da) | 2006-11-13 |
| EP1505965A1 (en) | 2005-02-16 |
| RU2334512C2 (ru) | 2008-09-27 |
| RU2004136583A (ru) | 2005-09-10 |
| IL164774A (en) | 2010-04-29 |
| US20050197372A1 (en) | 2005-09-08 |
| ES2268403T3 (es) | 2007-03-16 |
| DE60307265D1 (de) | 2006-09-14 |
| CN100408035C (zh) | 2008-08-06 |
| TWI299663B (en) | 2008-08-11 |
| EP1505965B1 (en) | 2006-08-02 |
| NO20045245L (no) | 2004-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sankaranarayanan et al. | How does chronic atrial fibrillation influence mortality in the modern treatment era? | |
| NZ716245A (en) | Fused benzoxazepinones as ion channel modulators | |
| NI201000034A (es) | Activadores de guanilato ciclasas solubles. | |
| ATE334677T1 (de) | Verwendung des metabolits von valsartan zur hemmung der thrombozytenaggregation | |
| NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
| EA201100756A1 (ru) | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенным профилем безопасности по сравнению со стандартным лечением варфарином | |
| NO20082790L (no) | Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion | |
| NO20083036L (no) | Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon | |
| WO2010042163A3 (en) | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders | |
| ATE366724T1 (de) | Kondensierte heterocyclische derivate | |
| EP1125580A3 (en) | Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors | |
| MY141034A (en) | Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use | |
| WO2007062028A8 (en) | Treatment of qt interval prolongation and diseases associated therewith | |
| DK1973541T3 (da) | Anvendelse af benzokondenserede heterocykliske sulfamidderivater til nedsættelse af lipid- og blodglucoseniveauer | |
| RU2011138955A (ru) | Производные 1, 4-бензотиазепин-1-оксида и фармацевтическая композиция с использованием таких соединений | |
| JP2013514981A5 (https=) | ||
| DE60329323D1 (de) | Substituierte heterozyklische verbindungen | |
| JP2007514769A5 (https=) | ||
| BRPI0508054A (pt) | bloqueadores kv1.5 para o aumento seletivo da contratilidade auricular e tratamento da insuficiência cardìaca | |
| DE602004027515D1 (de) | Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz | |
| Güvenç et al. | A novel explanation for the cause of atrial fibrillation seen in atherosclerotic coronary artery disease:“downstream inflammation” hypothesis | |
| Napoli et al. | Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension | |
| AR042000A1 (es) | Uso de fosinopril para reducir los eventos cardiovasculares en pacientes dializados | |
| TW200700412A (en) | Factor xa inhibitor crystalline forms | |
| Mishima et al. | Risk Assessment of Asymptomatic Paroxymal Atrial Fibrillation by Using the P-Wave Signal-Averaged Electrocardiogram in Patients with Chronic Kidney Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1505965 Country of ref document: EP |